The Chemical Biological Medical Systems Joint Vaccine Acquisition Program (CBMS-JVAP) is the organization responsible for developing, producing and stockpiling FDA-licensed vaccine systems to protect the military personnel from biological agents. The current CBMS-JVAP portfolio includes vaccines at varying stages of clinical development in addition to FDA licensed vaccines.
CBMS-JVAP yesterday issued a Request for Information (RFI) seeking input from manufacturers with the capability to deliver a Good Manufacturing Practices (GMP) product that will be suitable for use in humans by the government to support non-clinical and Phase 1 studies under an Investigational New Drug (IND) application. Specifically, the government is seeking a manufacturer with the capability to conduct manufacturing of government owned Virus Like Particles (VLPs) vaccines. The government plans to initiate manufacturing efforts in early 2013.
Companies with the experience and the capability to develop, manufacture and produce a VLP vaccine under cGMP manufacturing conditions are invited to respond to the RFI.
Further details are available under Solicitation Number: W911QY-12-S-0018. The response deadline is June 13, 2012.
